Skip to main content
All Posts By

laurabbook@gmail.com

American Lung Association logo
What Can you Expect from a Lung Cancer Clinical Trial AdvocacyResearchTreatments

What Can you Expect from a Lung Cancer Clinical Trial

*November 2021* In this webinar, Dr. Mark A. Socinski, Executive Medical Director, Advent Health Cancer Institute, Orlando, FL, will explain the process of participating in a lung cancer clinical trial from beginning to end. Dr. Socinski will explain how typical lung cancer clinical trials are structured, how patients are monitored…
laurabbook@gmail.com
December 7, 2021
EGFR Resisters logo
EGFR Resisters and LCRF Research Partnership: First Study Grant Awarded! FundingResearchTreatments

EGFR Resisters and LCRF Research Partnership: First Study Grant Awarded!

*December 2021* Our first $150,000 LCRF grant awarded to Yang Tian, PhD from the Icahn School of Medicine at Mount Sinai. Her project is titled, “Targeting lung lineage plasticity to suppress Osimertinib-induced drug-tolerant persisters. Please view the announcement of this lung cancer study video here.
laurabbook@gmail.com
December 7, 2021
NIH Library of Medicine
Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation ResearchTreatments

Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation

*October 2021* Purpose: This study aimed to explore the clinical value of SBRT for primary lung lesions of EGFR-mutant NSCLC patients with non-oligometastatic disease during first-line EGFR-TKI treatment. Methods: We identified patients with stage IV EGFR-mutant non-oligometastatic NSCLC who were suitable to receive SBRT for the primary tumors after EGFR-TKI treatment. All…
laurabbook@gmail.com
November 12, 2021
Onc Live
Uncommon EGFR Mutations Come Into Focus With Novel NSCLC Therapies ResearchTreatments

Uncommon EGFR Mutations Come Into Focus With Novel NSCLC Therapies

*October 2021* The understanding of EGFR signaling in non–small cell lung cancer (NSCLC) continues to evolve, helping to spark the development of novel therapies for new patient populations with uncommon alterations. In May, the FDA granted an accelerated approval to amivantamab-vmjw (Rybrevant) for patients with locally advanced or metastatic NSCLC…
laurabbook@gmail.com
November 12, 2021
Cancer Network
Sintilimab Meets Primary End Point in ORIENT-31 Trial for EGFR+ Non-Squamous NSCLC ResearchTreatments

Sintilimab Meets Primary End Point in ORIENT-31 Trial for EGFR+ Non-Squamous NSCLC

*October 2021* Sintilimab with or without a bevacizumab biosimilar injection, combined with chemotherapy yielded promising findings in a population of patients with EGFR-mutant nonsquamous non–small cell lung cancer who have previously been treated with an EGFR tyrosine kinase inhibitor. Sintilimab (Tyvyt) has yielded a promising improvement to progression-free survival (PFS)…
laurabbook@gmail.com
November 12, 2021
Lung Cancer Journal
Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure ResearchTreatments

Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure

*July 2021* Highlights Pemetrexed-carbo plus bevacizumab and atezolizumab was effective in EGFR mutated lung cancer. Median PFS of 9.4 months, 1 year OS 72.5% in this heavily pretreated population were remarkable. Having similar efficacy, this regimen gave less toxicity compared with IMPower150 regimen. QoL was well preserved in patients which used pemetrexed…
laurabbook@gmail.com
November 12, 2021
Targeted Oncology
New Mechanisms Under Study to Overcome Osimertinib Resistance in EGFR+ NSCLC ResearchTreatments

New Mechanisms Under Study to Overcome Osimertinib Resistance in EGFR+ NSCLC

*October 2021* Several small molecule EGFR tyrosine kinase inhibitors (TKIs) are now available for the treatment of EGFR-mutated non–small cell lung cancer (NSCLC). However, progression after TKI therapy—including with the third-generation TKI osimertinib (Tagrisso)—is inevitable. Results of several studies targeting new treatment strategies were reported at the recent International Association for…
laurabbook@gmail.com
November 12, 2021